Mirati Therapeutics said a committee of the European medicines regulator has recommended approval of its treatment for a type of lung cancer. A committee of the European Medicines Agency backed Crasati after a re-examination of the drug, which the panel refused to grant in July, saying the requirements for conditional support had not been met, something Mirati disagreed with.